Nach den Spekulationen um das Dahinscheiden von FightAids@home hier eine Kopie der Mail von heute morgen:
Ciao, Michael.Dear FightAids@Home Members,
Good news! The FightAIDSatHome project has successfully concluded Phase I and is now in the process of entering Phase II. We want to thank you for your indispensable contribution to research in developing more effective AIDS therapeutics and give you the opportunity to contribute to the continued research and analysis that will be undertaken in Phase II.
FightAIDSatHome is a computational research project partnership between Entropia and the Olson laboratory at The Scripps Research Institute. FAAH accelerates AIDS research by generating and testing candidate drug compounds against detailed models of evolving AIDS viruses. Dr. Arthur Olson, Director of the Molecular Graphics Laboratory at TSRI, is the FAAH project leader. With the shift from Phase I to Phase II, the program will become entirely self-managed. As part of that process, Entropia is transitioning the project over to the Olson Laboratories at TSRI, where it will become a wholly non-profit endeavor. In compliance with our membership privacy policy, no personal member information will transfer; you must re-enlist (visit http://fightaidsathome.org/phase2.html) with the FAAH project to participate in Phase II.
Over the course of the FAAH project, nearly 60,000 machines in 20 countries have been involved in the project, logging just shy of 1,400 years of continuous computing and performing over nine million tasks. These contributed resources effectively functioned as a computer with 14 terabytes of memory and 1,335 terabytes of disk space. Peak power for this virtual supercomputer was 31 trillion calculations per second). For your convenience, Phase I statistics will remain available during the month of May.
Thanks to member-contributed computing resources, millions of drug docking computations have been run on the FAAH network during the past two and a half years. The project has ably demonstrated that with such massive computational abilities, researchers can utilize intensive approaches to identify drug candidates that succumb to resistance mutations and those that are more resilient to such mutations. An early lead developed during Phase I, TL-3, Has been shown to be promising against the drug resistant strains that have arisen from the currently approved HIV Protease inhibitors. The characteristics of TL-3 have been born out by the FAAH computational work.
Phase II will build on this research foundation but will run even more massive co-evolutionary computations to look for optimal drug characteristics in evading resistance mutations. As more data become available, it will be integrated into the computations with the goal of developing even smarter strategies for HIV therapeutics. We invite you to click here or visit http://fightaidsathome.org/phase2.html to learn how you can take part in this exciting new phase.
Again, thank you for your invaluable contribution to the success of this important project.
